Research and Markets: Familial Chylomicronemia (Type I Hyperlipoproteinemia) Pipeline Review, H2 2015 - Analysis & Forecasts

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/7g65nl/familial) has announced the addition of the "Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2015" report to their offering.

The report Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2015', provides an overview of the Familial Chylomicronemia (Type I Hyperlipoproteinemia)'s therapeutic pipeline.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  • The report provides a snapshot of the global therapeutic landscape of Familial Chylomicronemia (Type I Hyperlipoproteinemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Familial Chylomicronemia (Type I Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

Benefits of this Report:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics

Companies Mentioned:

  • Aegerion Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • CymaBay Therapeutics, Inc.
  • Kadmon Corporation, LLC
  • Novartis AG

For more information visit http://www.researchandmarkets.com/research/7g65nl/familial

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals